From: Cystatin C and long term risk of community-acquired sepsis: a population-based cohort study
Variable | Unadjusted Models | Add sociodemographics* | Add health behaviors ā | Add chronic medical conditions ā” | Add eGFR and ACR | Add hsCRP | Add eGFR, ACR and hsCRP |
---|---|---|---|---|---|---|---|
Cystatin C ā¤1.12 mg/dL | Referent | Referent | Referent | Referent | Referent | Referent | Referent |
Cystatin C >1.12 mg/dL | 2.70 (2.43-3.00) | 2.12 (1.89-2.37) | 2.06 (1.84-2.31) | 1.75 (1.55-1.96) | 1.57 (1.38-1.79) | 1.67 (1.48-1.87) | 1.51 (1.32-1.72) |
eGFRā„60 ml/min/1.73m2 | Referent | Ā | Ā | Ā | Referent | Ā | Referent |
eGFR<60 ml/min/1.73m2 | 2.38 (2.10-2.70) | --- | --- | --- | 1.13 (0.98-1.32) | --- | 1.14 (0.98-1.32) |
ACR <30 mg/g | Referent | Ā | Ā | Ā | Referent | Ā | Referent |
ACR ā„30 mg/g | 2.22 (1.97-2.49) | --- | --- | --- | 1.57 (1.38-1.79) | --- | 1.45 (1.28-1.65) |
hsCRP ā¤3.0 mg/dL | Referent | Ā | Ā | Ā | Ā | Referent | Referent |
hsCRP >3.0 mg/dL | 1.71 (1.54-1.90) | --- | --- | --- | --- | 1.51 (1.35-1.68) | 1.48 (1.32-1.65) |